Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1316 (sc) + Carboplatin + Etoposide in First-line Extensive Stage Small Cell Lung Cancer
NCT07009457Phase 1Active, not recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jun 2025
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of adebrelimab in small cell lung cancer (SCLC) (3 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Serum trough concentration at 28 days, Area under the concentration curve from time 0 to 21 days and 1 more. Started Jun 2025; status: active, not recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07009457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07009457.